<DOC>
	<DOCNO>NCT03031184</DOCNO>
	<brief_summary>This clinical trial evaluate whether Mirtazapine Carbamazepine effective placebo treat agitation people dementia . The trial ass safety , clinical cost effectiveness treatment . Participants randomise receive one treatments 12 week follow one year , blind trial .</brief_summary>
	<brief_title>Study Mirtazapine Carbamazepine Agitation Dementia</brief_title>
	<detailed_description>Patient-centred care , without use medicine offer first course treatment agitation dementia . However , need second line treatment fail , moment antipsychotic commonly prescribe , little research do safer alternative treatment . There medicine available treat agitation and/or aggression dementia , clear treatment work best . This research study design help answer , compare 2 medicine placebo ( tablet design look like medicine active medicine ) see either suitable treat agitation dementia . The medicine test Mirtazapine Carbamazepine . If participant family/carers agree take part study , participant prescribe treatment 12 week . Participants follow 1 year , assessment session 26 52 week . Participants take part study randomly allocate treatment group ( select treatment group chance ) . The study blind , mean participant 's doctor research team know treatment participant take study end . This necessary trial fair test treatment work best , however possible find medicine take event medical emergency . The study entirely voluntary participant wish join study must complete informed consent form ( lack capacity participant 's representative may behalf ) . Each participant must also nominated carer consent question aspect participant 's dementia/care experience care participant . The investigator aim recruit 471 patient study total 8 different region across UK .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Patients clinical diagnosis probable possible Alzheimer 's Disease use National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criterion ( McKhann et Al , 1984 ) diagnosis coexist agitated behaviour evidence agitate behaviour respond management accord AS/DH algorithm ( AS/DH , 2011 ) If patient take cholinesterase inhibitor memantine must stable dose ( defined three month current dose ) An assessment Cohen Mansfield Agitation Inventory ( CMAI ; CohenMansfield et al , 1989 , Long form ) score 45 great Written inform consent enter randomise trial Availability suitable informant ( consent identifiable family carer pay carer ) provide information carercompleted outcome measure consent take part trial . Current treatment antidepressant ( include MAOIs ) , anticonvulsant , antipsychotic . Patients must complete treatment medication least two week trial drug administration . Contraindications administration carbamazepine mirtazapine per current SmPCs Patients second degree atrioventricular block ( patient third degree heart block , pace maker fit , may include PI discretion ) Patient history bone marrow depression history hepatic porphyria Cases critical randomisation ( ie suicide risk patient present risk harm others ) Female subject age 55 childbearing potential , defined follow : postmenopausal female least 12 month spontaneous amenorrhea 6 month spontaneous amenorrhoea serum FSH &gt; 40mIU/ml female hysterectomy bilateral oophorectomy least 6 week prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Agitation</keyword>
	<keyword>Agitated behaviour</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>